Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v13-EN Version v8-FR
Language English French
Date Updated 2021-01-26 2020-09-30
Drug Identification Number 00723754 00723754
Brand name APRESOLINE APRESOLINE
Common or Proper name HYDRALAZINE HYDROCHLORIDE FOR INJECTION HYDRALAZINE HYDROCHLORIDE FOR INJECTION
Company Name STERIMAX INC STERIMAX INC
Ingredients HYDRALAZINE HYDROCHLORIDE HYDRALAZINE HYDROCHLORIDE
Strength(s) 20MG 20MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 10 VIALS 10 VIALS
ATC code C02DB C02DB
ATC description ARTERIOLARSMOOTH MUSCLE, AGENTS ACTING ON ARTERIOLARSMOOTH MUSCLE, AGENTS ACTING ON
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date
Actual start date 2019-08-21 2019-08-21
Estimated end date 2021-02-01 Unknown
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments Product is on 125% allocation at McKesson. Product is on 125% allocation at McKesson.
Health Canada comments